Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02), Zacks reports.
Centessa Pharmaceuticals Stock Performance
Shares of CNTA traded up $0.99 on Wednesday, reaching $12.00. The company’s stock had a trading volume of 465,287 shares, compared to its average volume of 303,845. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.37 and a quick ratio of 10.37. The stock has a market capitalization of $1.21 billion, a P/E ratio of -8.62 and a beta of 1.40. The stock’s 50 day simple moving average is $9.65 and its two-hundred day simple moving average is $9.84. Centessa Pharmaceuticals has a 12-month low of $5.15 and a 12-month high of $12.45.
Wall Street Analyst Weigh In
CNTA has been the subject of several research reports. Oppenheimer initiated coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, July 18th. They issued an “outperform” rating and a $14.00 price target for the company. Morgan Stanley raised their price objective on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research note on Friday, June 21st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.00.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.
Recommended Stories
- Five stocks we like better than Centessa Pharmaceuticals
- How Can Investors Benefit From After-Hours Trading
- Canopy Growth Stock: Can It Sustain Recent Gains?
- Best Stocks Under $10.00
- Serve Robotics Is Serving Up a Selling Opportunity
- How to Calculate Options Profits
- Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
